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Abstract  22 
 Cocoa supplementation improves glucose metabolism in Zucker diabetic fatty (ZDF) rats via 23 
multiple mechanisms. Furthermore, cocoa rich-diets modify the intestinal microbiota composition both 24 
in humans and rats in healthy conditions. Accordingly, we hypothesized that cocoa could interact with 25 
the gut microbiota (GM) in ZDF rats, contributing to their antidiabetic effects. Therefore, here we 26 
investigate the effect of cocoa intake on gut health and GM in ZDF diabetic rats.  27 
 Male ZDF rats were fed with standard (ZDF-C) or 10% cocoa-rich diet (ZDF-Co) during 10 28 
weeks. Zucker Lean animals (ZL) received the standard diet. Colon tissues were obtained to determine 29 
the barrier integrity and the inflammatory status of the intestine and faeces were analysed for microbial 30 
composition, short-chain fatty acids (SCFA) and lactate levels. We found that cocoa supplementation 31 
up-regulated the levels of the tight junction protein Zonula occludens-1 (ZO-1) and the mucin 32 
glycoprotein and reduced the expression of pro-inflammatory cytokines such as tumour necrosis factor-33 
α (TNF-α), interleukin-6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) in the colon of ZDF 34 
diabetic animals. Additionally, cocoa modulated the microbial composition of the ZDF rats to values 35 
similar to those of the lean group. Importantly, cocoa treatment increased the relative abundance of 36 
acetate-producing bacteria such as Blautia and prevented the increase in the relative amount of lactate-37 
producing bacteria (mainly Enterococcus and Lactobacillus genera) in ZDF diabetic animals. 38 
Accordingly, the total levels of SCFA (mainly acetate) increased significantly in the faeces of ZDF-Co 39 
diabetic rats. Finally, modified GM was closely associated with improved biochemical parameters 40 
related to glucose homeostasis and intestinal integrity and inflammation. 41 
 These findings demonstrate for the first time that cocoa intake modifies intestinal bacteria 42 
composition towards a healthier microbial profile in diabetic animals and suggest that these changes 43 
could be associated with the improved glucose homeostasis and gut health induced by cocoa in ZDF 44 
diabetic rats. 45 
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Highlights.  50 
- Intestinal barrier integrity is improved in diabetic rats submitted to cocoa diet 51 
- Cocoa diet prevents intestinal inflammation in diabetic rats 52 
- Cocoa diet modifies gut microbiota to a healthier microbial profile in diabetic rats 53 
 - Total levels of short-chain fatty acids increases in diabetic rats fed on cocoa 54 
55 
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1.- Introduction 56 
 Diabetes is a complex metabolic disorder characterized by hyperglycaemia resulting from 57 
defects in insulin secretion and insulin action (ADA, 2017). At present, prevalence of type 2 diabetes 58 
(T2D) is reaching epidemic proportions, becoming a serious threat to public health worldwide mainly 59 
due to  the associated complications (WHO, 2016). The growing prevalence of T2D is positively 60 
related to harmful lifestyles, in particular the reduced levels of physical activity and increasingly 61 
unhealthy eating habits, indicating that diet plays a crucial role in the onset and progression of T2D 62 
(WHO, 2016). More importantly, an increasing body of evidence suggests that certain dietary 63 
compounds may attenuate the risk of T2D by their ability to modulate gut microbiota (GM) 64 
composition (Nie et al., 2019).  65 
 The GM comprises a complex community of bacteria that colonizes the surface and the lumen 66 
of the gastrointestinal tract. Microbiota transform food components and produce a wide range of 67 
derived metabolite that impact host’s physiology and health in many ways, from the maintenance of 68 
intestinal homeostasis to energy metabolism (Van Treuren & Dodd, 2020). Indeed, many disease states 69 
have been associated with alterations in microbiota composition and consequently on their 70 
functionality, indicating that GM could be involved in the development of numerous pathologies 71 
(Danneskiold-Samsoe et al., 2019). In particular, microbiota function has been identified as a relevant 72 
and potentially modifiable factor that contributes to the development of metabolic diseases, including 73 
T2D (Li, Watanabe & Kimura, 2017). Therefore, interventions targeting GM are emerging as 74 
promising effective strategies for the prevention and management of T2D.  75 
  Polyphenols are a large group of phytochemical compounds that have attracted much interest 76 
due to their beneficial properties. Accumulating evidences suggest that dietary polyphenols may 77 
interact with GM (Nash et al., 2018; Tomás-Barberán & Espín, 2019). Bioavailability of dietary 78 
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polyphenols in the digestive tract is highly variable. Aglycones, monomeric and dimeric structures can 79 
be absorbed in the small intestine. However, most of polymeric structures  reach the colon intact where 80 
they are metabolized by GM producing small microbial derived metabolites which are absorbed more 81 
efficiently and therefore may contribute to the beneficial health effects of polyphenols (González-82 
Sarrías, Espín, & Tomás-Barberán, 2017). In addition, these natural compounds modulate the 83 
composition and function of GM exhibiting prebiotic effects and antimicrobial action against 84 
pathogenic intestinal microbiota (Marchesi et al., 2016; Singh et al., 2019). In this way, polyphenols 85 
can influence the bacterial production of fermented or degraded metabolites (short chain fatty acids –86 
SCFA-) which can modulate multiple physiological pathways in several tissues, affecting gut health, 87 
glycaemic control, lipids profile and insulin resistance (Morrison, & Preston, 2016). Therefore, a more 88 
complete understanding of this bidirectional interaction between polyphenols and GM should help to 89 
explain the beneficial health effects of these natural compounds. 90 
 Cocoa is considered a rich source of dietary polyphenols, mainly flavanols such as epicatechin 91 
and procyanidins. Cocoa flavanols can exert antidiabetic effects via multiple mechanisms, including 92 
antioxidant and anti-inflammatory effects, as well as by increasing insulin secretion and insulin action 93 
(Martín, Goya, & Ramos, 2016). In addition, a cocoa rich diet has been described as able to modify the 94 
intestinal microbiota composition in healthy rats (Massot-Cladera et al., 2012; Massot-Cladera et al., 95 
2014), pigs (Jang et al., 2016; Magistrelli et al., 2016) and humans (Tzounis et al., 2011). Therefore, it 96 
is probable that interaction of cocoa components with GM actively contributes to the antidiabetic 97 
effects of cocoa. However,  to date, the influence of cocoa feeding on intestinal health and on the 98 
composition of GM in diabetes remains to be considered. Accordingly, the aim of the present study was 99 
to investigate whether cocoa supplementation modulate intestinal dysbiosis induced by diabetes in an 100 
in vivo model of T2D, using Zucker diabetic fatty (ZDF) rats. To this end, the effect of a cocoa rich-101 
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diet on glucose homeostasis and biomarkers of gut health in diabetic ZDF rats was evaluated. In 102 
addition, the compositional changes in GM and SCFAs induced by cocoa in diabetic animals were also 103 
determined.  104 
  105 
 8 
2. Material and Methods 106 
2.1. Diets, animals and experimental design 107 
 Diets were prepared from an AIN-93G formulation (Panlab S.L., Barcelona, Spain). Cocoa rich-108 
diet (10%) was produced by adding 100 g/Kg of natural Forastero cocoa powder (a kind gift from Idilia 109 
Foods, Barcelona, Spain) to AIN-93G diet. It contains epicatechin (382 mg/100 g), catechin (115 110 
mg/100 g) and procyanidins (167 mg/100 g) and non-flavonoid compounds such as theobromine 111 
(742mg/100 g). The resulting cocoa diet was isoenergetic and its composition is given in Table 1.  112 
 Male Zucker diabetic fatty (ZDF) rats (n=16) and their Zucker lean controls (ZL) (n=6) were 113 
obtained from Charles River Laboratories (L'arbresle, France) at 9 weeks of age. Animals were placed 114 
under standard controlled conditions (21 ºC ± 1 ºC; 12 h day/night cycle). After one week of 115 
acclimation, ZDF diabetic rats were randomly divided into two groups of eight animals that received 116 
the standard AIN-93G diet (ZDF-C) or the same control diet supplemented with 10 % of cocoa (ZDF-117 
Co) for 10 weeks. The lean Zucker rats (ZL) received the standard AIN-93G diet. During the 118 
experiment, food and water were available ad libitum. Food intake was monitored daily and animal 119 
weight and glycaemia was weekly followed. Animals were treated according to the European 120 
(2010/63/EU) and Spanish (RD 53/2013) legislation on Care and Use of Experimental Animals and the 121 
experiments were approved by the Ethics Committee from Comunidad de Madrid (PROEX 304/15).  122 
 123 
2.2. Biochemical determinations  124 
 At 20 weeks of age, animals were fasted overnight and were scarified by exsanguination under 125 
anaesthesia ketamine/xylazine (80 mg/8 mg Kg–1, i.p.). Blood samples were collected for biochemical 126 
analysis. Glucose was determined using an Accounted Glucose Analyzer (LifeScan España, Madrid, 127 
Spain) and insulin and glycosylated haemoglobin (HbA1c) were quantified by ELISA kits (Rat Insulin, 128 
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Mercodia, Uppsala, Sweden; HbA1c Kit Spinreact, BioAnalitica, Madrid, Spain). Fasting plasma 129 
concentrations of both glucose and insulin were used to calculate indices of  insulin resistance 130 
[homeostasis model assessment (HOMA)-IR] and secretion (HOMA-B) using the following formulae: 131 
HOMA-IR = fasting insulin (mU/ml) X fasting glucose (mM)/22.5; HOMA-B = 20 X fasting insulin 132 
(mU/ml)/[fasting glucose (mM)-3.5]. Triacylglycerols (TG), HDL-Cho and LDL-Cho were determined 133 
in serum by kits (BioSystems, Madrid, Spain) as described elsewhere (Álvarez-Cilleros et al., 2019). 134 
Tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels were quantified in serum samples by 135 
specific rat TNF-alpha Quantikine ELISA Kit (RTA00, R&D System, USA) and IL-6 DuoSet ELISA 136 
Kit (DY506, R&D System, USA) according to the manufacturer’s instruction. 137 
 138 
2.3. Glucose tolerance test (GTT) 139 
 GTTs were performed one week before the end of the study. Briefly, an overload of glucose 140 
(2g/Kg body weight) (Sigma Chemical, Madrid, Spain) was ip administered in animals subjected to 141 
overnight fasting. Blood samples were collected from the tail vein at five different time points (0, 30, 142 
60, 90, 120 and 180 min) and glucose levels were measured using an Accounted Glucose Analyzer 143 
(LifeScan España, Madrid, Spain). The integrated glucose response (area under the curve, AUC) over a 144 
period of 180 min after glucose overload was also calculated.  145 
 146 
2.4. Histologic and immuno-histochemical analysis 147 
 Rats were sacrificed at 20 weeks of age and the entire colon was resected and cleaned with PBS. 148 
Sections (2 cm) from the most distal portion of the colon were routinely processed and paraffin 149 
embedded for histological and immune-histochemical analyses. Sections were cut, stained with 150 
haematoxylin–eosin (H&E) or periodic-acid-Schiff (PAS) according to the manufacturer's instructions. 151 
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Images were obtained under light microscopy (Leica DM LB2) and a digital Leica DFC 320 camera 152 
(Leica, Madrid, Spain) and quantified with ImageJ software (Fiji image J; 1.52i, NIH, USA). The crypt 153 
depth was measured from H&E slices and was determined as number of cells per hemi-crypt. Only 154 
crypts with an open longitudinal crypt axis were analysed. The tissue expression level of the neutral 155 
mucin glycoprotein was determined by means of PAS and it was calculated as the number of PAS 156 
positive cells per crypt. 157 
 For the immuno-histochemical staining, antibodies against monoclonal anti-proliferating cell 158 
nuclear antigen (PCNA; PC-10) (Lab Vision Corporation and Bionova- Científica SL), Cyclin E (sc-159 
247, Santa Cruz Biotechnology),  p21 (sc-6246, Santa Cruz Biotechnology), Zonula occludens-1 (ZO-160 
1) (sc-10804, Santa Cruz Biotechnology), tumour necrosis factor-α (TNF-α) (sc-133192, Santa Cruz 161 
Biotechnology), interleukin-6 (IL-6) (sc-57315, Santa Cruz Biotechnology), monocyte chemoattractant 162 
protein 1 (MCP-1) (sc-52701, Santa Cruz Biotechnology) and CD45 (ab-10558, Abcam) were used. 163 
After deparaffinization and endogenous peroxidase quenching, serial colonic sections were incubated 164 
with the primary antibodies overnight at 4ºC. Secondary antibodies were used to detect primary 165 
antibodies, followed by streptavidin-tagged horseradish peroxidase and visualized by 3,3′-166 
diaminobenzidine (DAB) substrate (Sigma Chemical, Madrid Spain). The sections were counterstained 167 
with Harris’s haematoxylin, dehydrated and mounted. Brown colour indicates specific protein 168 
immunostaining and light blue colour indicates nuclear haematoxylin staining. Positive and negative 169 
controls were used during the optimization of the methods.  170 
 At least 20 perpendicular well-oriented crypts were examined in each animal under light 171 
microscopy at x400 magnification. The proliferative labelling index (LI) (%) was calculated as the 172 
number of positive nuclei × 100/total number of cells per crypt column height. ZO-1, TNF-α, IL-6, 173 
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MCP-1 and CD45 protein expression level was evaluated as percentage of the stained area to the total 174 
area per crypt by using the colour deconvolution plug-in from ImageJ v1.52j software. 175 
 176 
2.5. Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay.  177 
 Apoptotic colonic epithelial cells were labelled in situ by identifying DNA fragmentation on 178 
paraffin embedded sections using the terminal deoxynucleotidyl transferase UTP nick end labelling 179 
(TUNEL) assay. After deparaffinization and rehydration tissue sections were permeabilized with 180 
proteinase K (20 μg/mL) for 15 min at 37°C, and then treated with 3% hydrogen peroxide for 5 min to 181 
quench endogenous peroxidase activity. After sections were incubated with equilibration buffer for 10 182 
min, followed by immediate application of TdT-enzyme working for 1 h at 37ºC. Slices were incubated 183 
with peroxidase conjugated streptavidin and subsequent staining with DAB and counterstaining with 184 
methyl green. The apoptotic index represents the proportion of cells undergoing apoptosis within a 185 
crypt column (x400) and was calculated as the ratio of TUNEL-positive cells to the total number of 186 
cells counted within 50 full-length well orientated crypts.  187 
 188 
2.6. Faecal samples. 189 
 Fresh faecal samples were collected at the end of the intervention period, early in the morning, 190 
by abdominal massage in sterilized tubes and immediately frozen at –80ºC for future analyses. 191 
 192 
2.7. DNA extraction, and 16S gene PCR amplification. Illumina Mi-Seq sequencing.   193 
 DNA was extracted from faecal samples using G-spin columns (INTRON Biotechnology). 194 
DNA concentration was determined using Quant-IT PicoGreen reagent (ThermoFisher Scientific, Inc., 195 
Waltham, MA, USA) and around 3 ng were used to amplify the V3-V4 region of 16S rRNA gene 196 
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(Caporaso et al., 2011).  PCR products (approx. 450 bp) included extension tails, which allowed sample 197 
barcoding and the addition of specific Illumina sequences in a second low-cycle number PCR. 198 
Individual amplicon libraries were analysed using a Bioanalyzer 2100 (Agilent Technologies, Palo 199 
Alto, CA, USA) and a pool of samples was made in equimolar amounts. The pool was further cleaned, 200 
quantified and the exact concentration estimated by real time PCR (Kapa Biosystems). Finally, DNA 201 
samples were sequenced on an Illumina MiSeq instrument with 2 x 300 paired-end read sequencing at 202 
the Unidad de Genómica (Parque Científico de Madrid, Spain). 203 
 We used the BIPES pipeline to process the raw sequences (Zhou et al., 2011) and we performed 204 
UCHIME (implemented in USEARCH, version 6.1) to screen out and remove chimeras in the de novo 205 
mode (Edgar, & Flyvbjerg, 2015). In each sample between 90,000 and 220,000 sequences were 206 
identified. All subsequent analyses were performed using 16S Metagenomics (Version: 1.0.1.0) from 207 
Illumina. The sequences were then clustered to an operational taxonomic unit (OTU) using USEARCH 208 
with default parameters (USERACH61). The threshold distance was set to 0.03. Hence, when the 209 
similarity between two 16S rRNA sequences was 97%, the sequences were classified as the same OTU. 210 
QIIME-based alignments of representative sequences were performed using PyNAST, and the 211 
Greengenes 13_8 database was used as the template file. The Ribosome Database project (RDP) 212 
algorithm was applied to classify the representative sequences into specific taxa using the default 213 
database (Edgar, & Flyvbjerg, 2015). The Taxonomy Database (National Center for Biotechnology 214 
Information) was used for classification and nomenclature. Bacteria were classified based on the SCFA 215 
end-product as previously described (Wang, Garrity, Tiedje, & Cole, 2007). 216 
 217 
2.8. Measure of SCFAs and lactate in faeces 218 
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 Faecal samples were weighed and suspended in 1 mL of water with 0.5% phosphoric acid per 219 
0.1 g of sample and frozen at −20ºC immediately after collection. Once thawed, the faecal suspensions 220 
were homogenized with a vortex for about 2 min and centrifuged for 10 min at 17949 g. Aliquots of 221 
400 μL of supernatans were diluted with 100 μL of 4-methyl valeric acid used as internal standard at a 222 
final concentration of 788 μM and then the suspension was extracted with 1 mL of n-butanol for 21 223 
min and centrifuged for 105 min at 16000 g. A stock solution containing the mixture of standards 224 
(WSFA-2; Sigma-Aldrich, Madrid, Spain) was treated as samples and diluted to obtain a calibration 225 
curve ranging from 2 to 10000 μM. Internal standard was also added to the mixture of standards.  226 
 The analytes (2 μL) were injected in the splitless mode into an Agilent 7890A gas 227 
chromatography (GC) system (Agilent Technologies, Palo Alto, CA, USA) equipped with a 5975C 228 
mass spectrometer (MS) detector and an Agilent DB-WAXtr column (100% polyethilen glycol, 60 m, 229 
0.325 mm, 0.250 μm). Helium was used as a carrier gas at 1.5 mL/min. The column temperature was 230 
initially 50ºC, then increased to 150ºC at 15ºC/min, to 200ºC at 5ºC/min, and finally to 240ºC at 231 
15ºC/min and kept at this temperature for 20 min (total time 41.3 min). The MS was tuned during all 232 
experiments; the signal acquisition for quantification was done in the single-ion monitoring (SIM) 233 
mode. The temperature of the ionization source and the quadrupole were 230ºC and 150ºC, 234 
respectively. The electron-impact ionization energy was 70 eV. Concentrations of acetate, propionate 235 
and butyrate were expressed as µM/g of sample. 236 
 For lactate determination faecal samples were suspended in MilliQ water. After homogenization 237 
with an ultrasonic liquid processor Vibra-Cell CV18 (Sonics & Materials, Connecticut, Unites States), 238 
faecal suspensions were centrifuged at 1000 g for 5 min. The aqueous phase was filtered through a 0.2 239 
µm cellulose acetate syringe filter (VWR International, Barcelona, Spain). After filtration, lactate was 240 
measured with an Advanced Compact Ion Chromatographic instrument IC867 (Metrohm AG, Herisau, 241 
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Switzerland). Sodium L-lactate (Sigma-Aldrich, Madrid, Spain) was used as standard. Concentrations 242 
of lactate were expressed as µM/g of sample. 243 
2.9. Statistical Analysis 244 
  Data from biochemical and immune-histochemical parameters, relative abundances of taxa and 245 
SCFA levels were tested for normality and homogeneity of variances by the D’Agostino and Pearson 246 
and Levene tests, respectively; for multiple comparisons, one-way ANOVA was followed by a Tukey 247 
test when variances were homogeneous or by the Tamhane test when variances were not homogeneous. 248 
The level of significance was P < 0.05. A GraphPad Prism version 7.00 (GraphPad software, Inc., La 249 
Jolla, California) was used.  250 
 Shannon, Chao and Simpsons indexes were calculated to analyse α-diversity using QIIME. 251 
Reads in each OTU were normalized to total reads in each sample. Unsupervised classification studies 252 
with Principal Components Analysis (PCA) were carried out to analyse the differences between groups. 253 
Relationship strength between parameters was assessed using the two tailed Pearson’s correlation test. 254 
The correlation was considered significant only when the absolute value of Pearson’s correlation 255 
coefficient r was > 0.5.  256 
257 
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3. Results  258 
3.1. Physiological parameters 259 
 At the beginning of the study, ZDF animals showed marked increases in body weight as 260 
compared to ZL rats (210.0 ± 9,0 vs 284.4 ± 10.6 g, respectively; P < 0.05). However, fasted glycaemia 261 
was not significantly different between ZL and ZDF animals (84.6 ± 6.0 vs 102.2 ± 13.1 mg/dL, 262 
respectively; p < 0.05), which indicates that at this time point animals were at a pre-diabetic stage. 263 
Then, ZDF rats were randomly assorted to ZDF-C or ZDF-Co groups. The administration of cocoa for 264 
10 weeks reduced body weight in diabetic ZDF rats while daily food intake remained constant (Figures 265 
1A and 1B). Moreover, the increase in glycaemia, insulinaemia and HbA1c that is characteristic of 266 
ZDF rats was significantly reduced in those feed with cocoa diet (ZDF-Co) (Figures 1C-1D). Likewise, 267 
there was a significant reduction in insulin resistance state (HOMA-IR) and a significant increase in 268 
beta-cell function (HOMA-B) in ZDF-Co rats as compared to ZDF (Fig. 1D). Finally, the glucose 269 
tolerance test showed that diabetic ZDF-Co rats were less intolerant than ZDF-C rats and, 270 
consequently, their AUC value was significantly reduced by the cocoa rich diet (Figure 1G). In 271 
contrast, HDL-Cho, LDL-Cho and TG levels were significantly elevated in both diabetic ZDF groups 272 
in comparison to the ZL group and cocoa diet only was able to partly reduce the levels of LDL-Cho in 273 
ZDF animals (Figure 1H). Altogether, these results indicated that cocoa intake was able to improve 274 
glycemic control but not lipid profile in diabetic and obese ZDF rats.  275 
 276 
3.2. Intestinal integrity and inflammation 277 
 Next, we investigated the effect of cocoa treatment in the intestinal barrier integrity and colonic 278 
inflammation in diabetic rats. Morphological modifications at a scale larger than crypts were not 279 
observed. As shown in Figure 2A, diabetic ZDF-C rats revealed a similar crypt depth to the ZL lean 280 
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group whereas rats fed with cocoa presented a significantly larger crypt depth. Accordingly, colonocyte 281 
proliferation and apoptosis (Figures 2B and 2C) were similar in diabetic and lean animals while both 282 
processes were significantly increased in ZDF-Co animals, indicating that cocoa intake induced a faster 283 
renewal rate of the colonic epithelium. To deepen the mechanism by which cocoa intake increases the 284 
colon mucosa and its renewal, we also evaluated the expression patterns of cell cycle proteins such as 285 
cyclin E, a late G1 phase cyclin and CDK p21 inhibitors as indicator of cell proliferation activity in 286 
colonic mucosa. ZDF-Co rats showed increases in the cytosolic and diffuse distribution of positive 287 
nuclei expression of cyclin E, compared to ZL and ZDF-C groups. The high levels of cyclins E induced 288 
by cocoa might be explained, at least in part, by a coordinate decrease in p21, reducing their association 289 
with cyclins and finally aiding the progression of cell cycle (Supplementary Figure 1). Likewise, levels 290 
of the mucin glycoprotein, a crucial component of the mucus layer expressed in goblet cells, were also 291 
slightly but significantly increased in the diabetic animals fed with cocoa (Figure 2D). In addition, 292 
control diabetic animals showed a significant decrease in the levels of  one of the main tight junction 293 
proteins Zonula occludens-1 (ZO-1) in comparison with control lean group; interestingly, diabetic 294 
animals fed with cocoa not only prevented the ZO-1 decrease induced by diabetes but also showed ZO-1 295 
levels significantly higher than those of the lean group (Figure 2E).  Finally, the expression of pro-296 
inflammatory cytokines (TNFα, IL-6, and MCP-1) and the levels of CD45 (marker of immune cell 297 
infiltration) were significantly increased in the colonic mucosa of diabetic rats and they were partly 298 
prevented in those fed with cocoa (Figure 3A-D). The circulating levels of the cytokines IL-6 and TNF-299 
α in serum were not significantly different among ZL, ZDF-C and ZDF-Co rats (Figure 3E). Overall, 300 
these results indicate that cocoa diet to a large degree greatly maintains the intestinal integrity and 301 
generally reduced intestinal inflammation in diabetic rats. 302 
 303 
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3.3. Bacterial diversity and taxa composition 304 
 To analyse the effect of diabetes on gut microbial composition and the influence of a cocoa rich 305 
diet, we performed a metagenomic DNA sequencing of bacterial 16S rRNA gene regions V3-V4 of 306 
faecal samples. The total number of species identified was higher in ZDF-C rats when compared with 307 
ZL or ZDF-Co rats (Figure 4A). Likewise, Shannon, Simpsons and Chao indexes representing the 308 
richness and evenness of species diversity within each sample (α-diversity), were markedly augmented 309 
in control diabetic rats (Figures 4B-D). We also performed a bi-dimensional PCA of the bacterial 310 
community, which measures microorganism diversity between samples (β-diversity) in an 311 
unsupervised manner. The analysis revealed distinct clustering in each group (Figure 4E).  312 
 Microbiota in diabetic animals (ZDF-C) were characterized by a significant increase in the 313 
relative abundance of Proteobacteria (3.6 fold increase), Tenericutes (2.8 fold increase) and 314 
Actinobacteria (2.6 fold increase) phyla and a reduction of Verrucomicrobia phylum (by 76.9%) when 315 
compared with ZL non-diabetic animals (Figure 4F). Notably, with the exception of Verrucomicrobia 316 
phylum, the microbial changes induced by diabetes were totally prevented in animals that were fed 317 
with cocoa. In addition, cocoa significantly increased the relative percentages of Firmicutes (1.4 fold 318 
increase) and Deferribacteres phyla (9.3 fold increase) and decreased the relative abundance of 319 
Cyanobacteries phylum (by 74.9%) when compared to the ZDF group. Overall, colonic microbiota was 320 
dominated by the Firmicutes, Bacteroidetes, Proteobacteria and Verrumicrobia phylum which 321 
accounted for over 96.8%, 96.7% and 95.8% of total bacteria in ZL, ZDF-C and ZDF-Co groups, 322 
respectively. Interestingly, the most important and recognized biomarker of dysbiosis, the 323 
Firmicutes/Bacteroidetes (F/B) ratio, was significantly increased in both ZDF-C and ZDF-Co rats 324 
(Figure 4G).   325 
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 At the family level, twenty families were identified with a relative abundance greater than 1% 326 
(Figure 5A). Eleven of these families significantly modified their relative abundance with diabetes or 327 
cocoa (Figure 5B). In particular, in ZDF-C diabetic animals, the relative abundance of 328 
Enterobacteriaceae (a family of the Proteobacteria phylum) and of Enterococcaceae and 329 
Lactobacillaceae (families of the Firmicutes phylum)  increased whereas the abundance of 330 
Ruminococcaceae ( of the Firmicutes phylum) and Verrucomicrobiaceae ( of the Verrucomicrobia 331 
phylum)  decreased. Interestingly, except for the Verrucomicrobiaceae family, cocoa diet significantly 332 
prevented all these microbial changes induced by diabetes. Moreover, cocoa supplementation increased 333 
the abundance of Flavobacteraceae, Prevotellaceae and Sphingobacteriaceae (families from 334 
Bacteroidetes phylum) and Lachnospiraceae ( Firmicutes phylum) in diabetic animals. 335 
 Figure 6 shows the changes found at genus and species level. Twenty one genera were 336 
identified with abundance greater than one per cent and eleven of these were significantly modified by 337 
either diabetes or the cocoa diet. The major differences found in diabetic ZDF-C animals were 338 
observed in the genera Escherichia (mainly E. alberti species), Tepidibacter, Lactobacillus (with L. 339 
antri, L. hayakitensis and L. johmsonii as the most prevalent species) and Enterococcus (mainly E. 340 
lactis specie) that where significantly higher compared with non-diabetic ZL.Conversely, 341 
Faecalibacterium and Oscillospira genera were significantly lower in the ZDF-C group. Once again, 342 
cocoa diet was able to prevent all these intestinal microbiota changes in diabetic animals.However, 343 
both ZDF-C and ZDF-Co showed significantly decreased levels of Akkermansia genus when compared 344 
with ZL group, a finding that was also noticeable at the species levels (A. Muciniphila). Finally, cocoa 345 
treatment induced Blautia (mainly B. hansenii and B. wexleare species) and Flavobacterium and 346 




3.4. SCFA- and lactate-producing bacteria and levels of lactate and SCFA in faeces 350 
 Next, we analysed the changes in the relative abundance of lactate- and SCFA-producing 351 
bacteria (Figures 7A and 7C-F) as well as the lactate and SCFA levels in faeces (Figure 7B). The 352 
relative abundance of butyrate-producing bacteria was essentially unchanged in all groups (Figure 7A). 353 
However, we found that cocoa feeding significantly increased the relative abundance of acetate-354 
producing bacteria (mainly due to an induction in Blautia genus) (Figure 7C) that was accompanied by 355 
higher levels of acetate in faeces (Figure 7A). On the other hand, diabetic animals showed a significant 356 
increase in the amount of lactate-producing bacteria that was driven primarily by changes in 357 
Enterococcus and Lactobacillus genera (Figure 7E) and a significant reduction in the relative amount 358 
of propionate-producing bacteria that was reproduced for Akkermansia genus (Figure 7F). Accordingly, 359 
the levels of lactate were significantly higher in the faeces of diabetic animals while the levels of 360 
propionate were significantly lower. Notably, cocoa treatment partly prevented the increase in lactate-361 
producing bacteria and as a result the levels of  lactate and propionate were ower than those found in 362 
diabetic animals.  363 
 364 
3.5. Correlation of gut microbiota and disease biomarkers 365 
 Finally, to further explore the relationship between the significantly altered genera in the 366 
microbiota of diabetic animals and clinical parameters related to glucose and lipid metabolism as well 367 
as intestinal integrity and inflammation, we performed a Person correlation analysis (Figure 8). A 368 
strong positive association was found between the relative abundance of Enterococcus, Escherichia, 369 
Lactobacillus and Tepidibacter genera and the increase in body weight and in several biomarkers of 370 
glucose homeostasis and inflammation. However, the genera Oscillospira and Akkermansia showed 371 
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significantly negative correlations with all these parameters. Likewise, Fecalibacterium showed 372 
significantly negative correlations with increase in body weight, insulinaemia, HbA1c, LDL, TG, IL-6, 373 
CD45and MCP-1. Finally, the presence of Flavobacterium was also negatively associated with, 374 
glycaemia, TNF-α and CD45. On the other hand, increased ZO-1 levels were positively associated with 375 
Blautia and Flavobacterium and negatively linked with Enterococcus, Escherichia, Parabacteroides, 376 
Sutterella and Tepidibacter. 377 
  378 
  379 
380 
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4. Discussion 381 
 In the present study, we show for the first time that cocoa intake modifies the intestinal bacteria 382 
composition in ZDF diabetic animals towards a healthier microbial profile. Interestingly, some of the 383 
gut microbiota modifications induced by cocoa are closely associated with improved glucose 384 
homeostasis and gut health, suggesting that the beneficial effects of cocoa in diabetes could be 385 
mediated, at least in part, by modulation of the microbiota.  386 
 Early reports have revealed the potential anti-diabetic properties of cocoa both in vivo and in 387 
vitro (Martin, Goya, & Ramos, 2016). In agreement with this, here we show that cocoa 388 
supplementation partially alleviated  glucose and lipid control. More importantly, in this study we 389 
found that dietary cocoa was able to improve the structure and the barrier integrity of the colon mucosa 390 
in diabetic rats. The expression of the intestinal tight junction protein ZO-1 and the intestinal mucus 391 
levels are extremely important in maintaining intestinal barrier function (Dhar & McAuley, 2019; 392 
Andrade et al., 2015). Accordingly, in the present study, ZO-1 and mucin levels were significantly 393 
reduced in the colon of control ZDF rats. However, diabetic animals fed on cocoa showed significantly 394 
higher expression of mucin and ZO-1 than those of the lean group. These results suggest that cocoa diet 395 
may improve the barrier function and integrity of diabetic animals through enhancing the protein 396 
expressions of mucin and ZO-1. Supporting this it has been shown that the intake of Salvia 397 
miltiorrhiza, a natural source of phenolic acids, ameliorates the damaged barrier function of diabetic 398 
mice through enhancing the expressions of tight junction proteins decreased by streptozotocin (STZ) 399 
(Gu et al., 2017).Likewise, it has been proved that long term intake of anthocyanims promoted 400 
intestinal integrity in healthy mouse (Peng et al, 2019).Notably, the tight junction of intestinal mucosal 401 
cells prevents excessive entrance of endotoxins and other noxious agents into the circulation system 402 
and therefore attenuates the activation of local and systemic inflammatory responses (Balakumar et al., 403 
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2018). Accordingly, diabetic animals showed a significantly increase in inflammatory cytokines such 404 
as IL-6, TNFα and MCP-1 as well as in the levels of CD45 (marker of immune cell infiltration) in the 405 
colonic mucosa that were significantly reduced by cocoa intake. Although the levels of LPS coud not 406 
be assayed in the plasma of these animals, it could be highlighted that no significant differences in the 407 
levels of IL-6 and TNFα were found in plasma, which is consistent with previous data in ZDF rats at 408 
this age and fed on standard diet (Morales-Cano et al., 2019). Therefore, it could be suggested that the 409 
altered intestinal barrier function we described in ZDF rats is not sufficiently damaged to cause an 410 
overt metabolic endotoxemia. Overall, here we show that cocoa intake has the potential to improve gut 411 
barrier integrity in diabetic animals and to reduce colon inflammation emerging as an additional tool to 412 
ameliorate diabetes. Although the precise molecular mechanism behind this protective effect is still 413 
unclear, we hypothesize that it could be related in part to the potential changes induced by cocoa in 414 
intestinal bacteria of diabetic animals due to its prebiotic activity (Singh et al., 2019).  415 
 Metabolic disorders such as diabetes have been associated with altered microbiota composition 416 
(Li, Watanabe & Kimura, 2017). In this study, the composition of the GM in diabetic rats (ZDF-C) was 417 
significantly different compared with lean animals (ZL). At the phylum level, the main changes 418 
observed in diabetic animals were an increase in Proteobacteria and a decrease in Verrucomicrobia 419 
phyla whereas no significant differences were found in the relative abundance of Firmicutes and 420 
Bacteroidetes. Interestingly, microbiota in diabetic animals treated with cocoa differed between the 421 
diabetic control and the lean groups, suggesting that cocoa may have specific effects on the microbial 422 
community of diabetic animals. The reduction in Proteobacteria abundance in the ZDF-Co group can 423 
be attributed to the potential of cocoa polyphenols to modulate intestinal microbiota, These results are 424 
in concordance with those reported by Araujo et al. (Araujo et al., 2019), who observed a decrease in 425 
the abundance of the phyla Proteobacteria in the faeces of obese rats fed with an ethanolic extract of 426 
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bacupari rich in phenol derivatives.. However, cocoa supplementation failed to correct the increase in 427 
the Firmicutes/Bacteroidetes (F/B) ratio that is characteristic of murine genetic obese models 428 
(Vallianou et al., 2019). It has been recently suggested that the regulation of microbiota by polyphenols 429 
could be independent of the decrease in the F/B ratio (Yang et al., 2019). More importantly, a 430 
systematic review has revealed that this relationship between F/B ratio and obesity is not always 431 
consistent, suggesting changes in specific microbiota as main responsible for metabolic outcomes (Sze, 432 
& Schloss, 2016). According to that, we found that cocoa intake modified some key bacterial groups 433 
which may be related to the beneficial improvement on the glucose homeostasis and gut health induced 434 
in diabetic animals.  435 
 The relative abundance of Proteobacteria in diabetic ZDF-C animals was partly ascribed to a 436 
significant increase in bacteria that belong to Escherichia genus (Enterobacteriaceae family) that are 437 
widely known to cause intestinal pathologies in humans and animals (Shin, Whon, & Bae, 2016; Allen-438 
Vercoe & Jobin, 2014). Likewise, although the absolute abundance of the Firmicutes phylum was 439 
unchanged in diabetic rats, certain genera were significantly modified when compared with the control 440 
lean group. Particularly, Enterococcus and Lactobacillus genera were increased in diabetic animals 441 
whereas Oscillospora genus was decreased. Enterococcus is a bacterial group which includes potential 442 
pathogens that have been associated with gut dysfunction and inflammatory diseases (Lo Presti et al., 443 
2019). In contrast, Lactobacillus is classically considered a beneficial group of bacteria for their 444 
favourable effects on host metabolism; however, recent studies have indicated that the increase of this 445 
genus might be related to obesity and inflammatory conditions (Zeng et al., 2013; Ge et al., 2018), 446 
which is in concordance with our findings in diabetic animals. Similarly, Oscillospira genus is 447 
associated with anti-inflammatory effects in the gut and it has been reported to be less abundant in T2D 448 
and obese patients (Del Chieirico et al., 2017; Liu et al., 2018). Interestingly, cocoa diet strongly 449 
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prevented all these harmful changes observed in the gut microbiota of diabetic animals. These findings 450 
are in agreement with previous studies showing that quercetin and resveratrol attenuate serum 451 
inflammatory cytokines and improve glucose metabolism in high-fat diet-fed rats by modulating 452 
bacterial species associated with diseases and inflammation (Zhao et al., 2017). In the same way, 453 
modifications induced by cocoa intake on the GM of diabetic animals may play a key role in the 454 
beneficial effects on glucose metabolism and gut health.  455 
 It is interesting to note that the abundance of Akkermansia genus (phylum Verrucomicrobia) is 456 
low during obesity and diabetes (Vallianou et al., 2019). In addition, it has been demonstrated that 457 
polyphenol treatment induces the expression of A. muciniphila which correlated with improved body 458 
weight and glucose tolerance (Anhê et al., 2017). However, we found that cocoa supplementation failed 459 
to restore the reduced abundance of A. muciniphyla in diabetic animals even though glucose 460 
metabolism and gut health were significantly improved. Similar results have been reported in obese 461 
mice treated with resveratrol (Sung et al., 2017) or with polyphenol-containing extracts from cinnamon 462 
bark and grape pomace (Van Hul et al., 2018) showing improved glucose tolerance with reduced 463 
abundance of Akkermansia. As suggested by the authors (Van Hul et al., 2018), it is possible that 464 
polyphenols have varied prebiotic potential for A. muciniphila, In addition, several study design 465 
differences (origin of polyphenols, type of diet, animal model, age or pathological status) may also 466 
contribute to explain the divergence in results regarding the gut microbiota composition. Thus, further 467 
studies are required to explore the role of this bacterial group in type 2 diabetes.   468 
 Microbiota modulate the production of SCFA (mainly acetate, butyrate and propionate) which 469 
can modify the concentrations of several gut peptides involved in glucose metabolism, gut barrier 470 
function and energy homeostasis (Parada et al., 2019). Accordingly, cocoa as a prebiotic food can 471 
positively affect the growth of beneficial bacterial species (Singh et al., 2019). In particular, it has been 472 
 25 
shown that a cocoa rich-diet promotes the growth of butyrogenic-type bacteria such as Roseburia in 473 
pigs (Solano-Aguilar et al., 2018). However, we found that the levels of butyrate-producing bacteria 474 
were essentially unchanged amongs all experimental groups while the abundance of acetate producing 475 
bacteria was significantly increased in cocoa fed rats. In addition, cocoa feeding increased the relative 476 
abundance of Blautia, a bacterial group that has been negatively correlated with obesity and T2D 477 
(Rondanelli, et al., 2015; Inoue et al., 2017). This different prebiotic effect could be attributed to 478 
significant modifications in the gut environment during the diabetic milieu which lead to the dissimilar 479 
composition and distribution of the intestinal microbiota in healthy compared to diabetic animals.  480 
 Acetate can improve gut barrier function either by stimulating goblet cell differentiation or by 481 
the reinforcement tight junctions of epithelial cells (Morrison & Preston, 2016). In this regard, it has 482 
been recently shown, in an animal model of intestinal inflammation that the supplementation with 483 
polyphenols from grape peel significantly increased the production of SCFA (mainly acetate and 484 
butyrate) and the colonic protein levels of ZO-1 (Maurer et al., 2019). Similarly, in this study, the 485 
relative abundance of Blautia was directly associated with increased levels of ZO-1 and mucin. 486 
Moreover, cocoa diet also decreased the abundance of lactate producing bacteria (mainly Lactobacillus 487 
and Enterococcus) and thus the level of lactate (precursor of SCFAs) in faeces. Interestingly, 488 
correlation analysis showed that both genera were positively associated with body weight and 489 
biochemical parameters related to glucose homeostasis and intestinal integrity and inflammation. 490 
Increased lactate levels have been observed in both humans and animal models of T2D and obesity and 491 
have been also associated with inflammation (Wu et al., 2016; Nishitsuji et al, 2017). However, 492 
microbial produced lactate is generally converted into propionate or butyrate by a subset of lactate-493 
utilizing bacteria and it is unclear whether bacterial derived lactate contributes to the high levels of 494 
plasma lactate in diabetics. Additionally, it should be taken into account that gut microbiota produces 495 
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many other classes of metabolites such as SCFAs, bile acids and amino acid derivatives that may also 496 
have essential signaling functions (Van Treuren & Dodd, 2019). Altogether, here we show that cocoa 497 
could modulate GM and SCFAs production, contributing to the recovery of colon barrier function, 498 
attenuating inflammation and eventually improving glucose metabolism. Therefore, these results 499 
suggest that the modulation of GM might be one of the mechanisms involved in the antidiabetic effects 500 
of cocoa. Although we do not know whether the changes observed in fecal SCFAs concentration in 501 
both ZDF and ZDF-Co reflect similar variations in circulating SCFAs, it is reasonable to hypothesize 502 
that potential changes in systemic SCFAs levels could also contribute to the observed phenotypes of 503 
the animals.  504 
 One limitation of this study is the different levels of starch and fibre between control and cocoa 505 
diet. However, it has been shown that the intake of polyphenols improve the health effects of the 506 
intestinal microbiota by activating SCFA excretion, intestinal immune function, and other 507 
physiological processes (Kawabata et al., 2019). Therefore, after cocoa intake, the increase in SCFAs is 508 
not only due to its fibre content but also to other bioactive compounds mainly polyphenols and 509 
theobromine (Martín-Peláez et al., 2017). Further studies will clarify if the effect of cocoa on intestinal 510 
microbial populations can be ascribed to cocoa polyphenols and/or theobromine, to dietary fibre or to a 511 
possible synergistic activity of all of these dietary components. 512 
  In summary, the present study demonstrates for the first time that cocoa supplementation 513 
improves intestinal integrity and inflammation in ZDF diabetic rats. Moreover, cocoa intake modifies 514 
gut microbiome in ZDF diabetic rats towards a healthier profile and these changes have been closely 515 
associated with the improved glucose homeostasis and gut health found in the diabetic animals. 516 
Consequently, we suggest that modulation of GM by cocoa may be an important mechanism that could 517 
partly mediate beneficial metabolic effects in diabetic animals. Future studies using faecal 518 
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transplantation from cocoa fed donors could help to address whether or not the alterations in the gut 519 
microbiota found in ZDF-Co rats play a pivotal role in mediating the beneficial metabolic effects of 520 
cocoa. Likewise, the application of metabolomics to microbiota could provide a more complex analysis 521 
to finally advance in the knowledge of the ultimate causality. 522 
 523 
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Figure captions 715 
 716 
Figure 1.- Effect of cocoa diet in glucose and lipid homeostasis in Zucker lean (ZL), Zucker 717 
Diabetic rats fed control diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co). (A) 718 
Food intake. (B) Body weight. (C) Plasma glucose levels. (D) Plasma insulin levels. (E) Glycosylated 719 
haemoglobin (HbA1c). (F) Homeostasis model assessment (HOMA)-IR and HOMA-B. (G) Plasma 720 
glucose levels during GTT and total area under the curve calculated from the GTT data. (H) Levels of 721 
HDL, LDL and TG in serum. Data represent the means ± SD of 6-8 animals.  Means sharing the same 722 
letter are not significantly different from each other (P<0.05) 723 
 724 
Figure 2.- Effects of cocoa diet on colon mucosa of Zucker lean (ZL), Zucker Diabetic rats fed 725 
control diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co). (A) Representative 726 
haematoxylin–eosin (H&E) stained sections and crypts depth measured as cells number per hemicrypt 727 
of the distal colon mucosa (scale bar 10 µm). (B) Colonic epithelial apoptosis as revealed by terminal 728 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay (brown-positive nuclei) (scale 729 
bar 10 µm) and quantification of apoptotic cells by TUNEL labelling index (%). (C) Representative 730 
photographs for immunohistochemical staining of proliferating cell nuclear antigen (PCNA) (brown-731 
positive nuclei) (scale bar 10 µm) and PCNA labelling index (%) in colonic mucosa. (D) 732 
Representative images of mucine glycoprotein by PAS staining (magenta) and quantitative analysis of 733 
positive PAS staining cells (%) (scale bar 10 µm). (E) Representative IHC photographs of ZO-1 protein 734 
expression and the positive area staining (%) (brown-stained) (scale bar 10 µm).  Means sharing the 735 




Figure 3.- Effects of cocoa diet on intestinal inflammation of Zucker lean (ZL), Zucker Diabetic 739 
rats fed control diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co). Representative 740 
immunohistochemistry photomicrograph of TNF-α (A), IL-6 (B), MCP-1 (C) and CD45 (D) (brown-741 
stained) in distal colon and inmunoreactive score (scale bar 10 µm). Levels of TNF-α and IL-6 in 742 
plasma (E). Values are expressed as mean ± SD (n = 6-8).  Means sharing the same letter are not 743 
significantly different from each other (P<0.05) 744 
 745 
Figure 4.- Bacterial diversity and taxa composition in Zucker lean (ZL), Zucker Diabetic rats fed 746 
control diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co).  (A) Number of species 747 
identified. (B) Shannon, (C) Simpsons and (D) Chao indexes were measured to evaluate the α-748 
diversity. (E) Unsupervised PCA were carried out to analyse the β-diversity. Each principal component 749 
describes most of the variation between samples. (F) Composition of the most abundant bacterial phyla 750 
(>0.1%) expressed as a percent of total bacteria and pie graphs of most abundant phyla. (G) Firmicutes 751 
to Bacteroidetes ratio (F/B). Data represent means ± SD of 6–8 animals per condition.  Means sharing 752 
the same letter are not significantly different from each other (P<0.05) 753 
 754 
Figure 5.- Bacterial families composition in Zucker lean (ZL), Zucker Diabetic rats fed control 755 
diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co). (A) Distribution bar-plot of 756 
families with relative abundance greater than 1%. (B) Composition of the most abundant families 757 
modified with diabetes or with cocoa expressed as a percent of total bacteria. Data represent means ± 758 
SD of 6–8 animals per condition.  Means sharing the same letter are not significantly different from 759 
each other (P<0.05) 760 
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 761 
Figure 6.- Genera and species composition in Zucker lean (ZL), Zucker Diabetic rats fed control 762 
diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet (ZDF-Co). (A) Distribution bar-plot of genera 763 
with relative abundance greater than 1%. (B) Composition of the most abundant bacterial genera 764 
modified with diabetes or with cocoa expressed as a percent of total bacteria. (B) Composition of the 765 
most abundant bacterial species modified with diabetes or with cocoa expressed as a percent of total 766 
bacteria. Data represent means ± SD of 6–8 animals per condition.  Means sharing the same letter are 767 
not significantly different from each other (P<0.05) 768 
 769 
Figure 7.- SCFA- and lactate-producing bacteria and SCFA and lactate faeces levels in Zucker 770 
lean (ZL), Zucker Diabetic rats fed control diet (ZDF-C) and Zucker Diabetic rats fed cocoa diet 771 
(ZDF-Co). (A) Sum of all SCFA- and lactate-producing genera expressed as a percent of total bacteria. 772 
(B) Acetate, butyrate, propionate and lactate levels in faeces. (C–F) Most abundant acetate-, butyrate-, 773 
propionate- and lactate-producing genera expressed as a percent of total bacteria. Data represent means 774 
± SD of 6–8 animals per condition.  Means sharing the same letter are not significantly different from 775 
each other (P<0.05) 776 
  777 
Figure 8.- Correlation analysis between gut microbiota and host parameters in diabetic rats. (A) 778 
Heatmap of correlation between the main significantly altered genera in the gut microbiota and host 779 
parameters related to diabetes and intestinal integrity and inflammation. Pearson correlation values 780 
were used for the matrix. The intensity of the colour represents the degree of association. *Denotes 781 
adjusted P < 0.05.  782 
783 
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